Lupin Financial and Company Overview
North America: Investing to increase complex share
Leadership: Delivering ~5.5%
TRX Gx volume of the U.S.1
New product sales driving US
growth ($ mn)
US quarterly sales ($ mn)
DE
Growing Respiratory
portfolio
R
#3
圄 #1
177
175
159
121
20.5%
Albuterol market
in the US¹
in 41 products²
share
Maintaining
leadership
Top 3 in 109
products²
In generics
-3% YoY
Q1 FY23 Q2FY23 Q3FY23 Q4FY23
-1% QoQ
•
•
Q4 FY23 Key Highlights
Focused on profitable growth in base portfolio
Continued strength in in Q4FY23
Total 9 launches in FY23 with Suprep performing well
•
USFDA Inspections: Vizag, Lupin Bio-research center
and Pharmacovigilance had zero observations
Note:
IQVIA Qtr Gx Mar-23 by prescriptions
1.
2.
iQVIA Qtr Mar-23 NSP data
48.0%
Arfometerol
market share
Brand + generic
LUPIN
●
•
.
Evolving Complex Product Portfolio through
investments in Injectables, Inhalation and Biosimilars
Current pipeline includes 55 FTFs incl. 22 exclusive FTF
Substantial investments in Inhalation, Injectables and
Biosimilars pipeline and capabilities (Development and
Manufacturing)
155 ANDAS pending approval; 30+ strong pipeline of
Injectables (filed + under development)
10View entire presentation